Juno Therapeutics, a Seattle-based immunotherapy developer, has filed for an initial public offering with the goal of securing as much as $150 million. The firm plans to use some of the money to advance clinical development of its cancer drug candidates.
Bedford, Mass.-based Ocular Therapeutix secured $65 million in an initial public offering, slightly less than the target amount announced two weeks ago. The biotech firm specializes in developing sustained-release eye disease treatments.
CardioDx, which specializes in noninvasive cardiovascular disease diagnostic tests, has revived its plans to launch an initial public offering although it did not disclose its IPO target. Meanwhile, U.K. device firm Lombard Medical Technologies has moved ahead with its U.S. IPO, obtaining $55 million from the sale of 5 million company shares.
Talecris Biotherapeutics filed updated documents with the Securities and Exchange Commission, suggesting it might go public to raise as much as $1 billion. A company spokeswoman said the North Carolina firm is "always exploring opportunities," but she declined to comment specifically on a possible initial public offering.
In a rare case of successful first-day trading among an early-stage medical device company, Northstar Neuroscience's initial public offering sold 7.1 million shares above its expected price range. The Seattle-based company develops medical devices for treating stroke and currently is conducting clinical trials on a device implanted in a patient's brain to improve recovery.